PHARMANOVIA
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its endocrinology portfolio with a new licensing agreement for GHRYVELIN™ (macimorelin), a novel medicine used for diagnosing Adult Growth Hormone Deficiency (AGHD) from Aeterna Zentaris.
The agreement gives Pharmanovia the exclusive commercial rights in the UK and EEA.
AGHD is a rare and serious condition that affects 2 to 3 people in 10,000 with significant risk of morbidity and reduced quality of life. It is underdiagnosed and often missed in patients.1
It is characterised by a number of variable and common symptoms including reduced energy levels, altered body composition, osteoporosis (reduced bone mineral density), reduced muscle strength, lipid abnormalities such as increased LDL cholesterol, insulin resistance, and impaired cardiac function.2
Pharmanovia CEO, Dr James Burt commented; ‘’Endocrinology is the largest of our four core therapy areas and the in-licensing of this important novel medicine, the second in-licensing deal of a novel medicine in almost as many weeks, speaks to our ability to in-licence novel, complementary products in the therapeutic settings we support.”
“We are well placed to use the knowledge and the platform we’ve built through our current endocrinology work to ensure that more patients get the diagnosis they need for this rare and serious condition. Furthermore today’s announcement presents a rare opportunity to license in a medicine that naturally synergises with one of the core growth products in our current portfolio.”
Dr Klaus Paulini, CEO of Aeterna Zentaris, added: “Pharmanovia has expertise marketing diagnostic testing solutions combined with an established footprint in endocrinology across Europe, so this partnership was a natural choice. We’re excited to leverage their knowledge to ensure that more patients benefit from an improved testing experience and reduction in unnecessary treatment for patients.”
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercialising a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.
About Macimorelin
Macimorelin is marketed under the brand name GHRYVELIN™ (macimorelin) in the UK and European Economic Area.
GHRYVELIN™ a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of GHRYVELIN™ for the assessment of AGHD. of GHRYVELIN™ was granted in 2019, based on Phase III data showing that oral macimorelin provides accuracy comparable to that of standard insulin tolerance testing (ITT)4, but has a more favourable safety profile compared to ITT. Oral GHRYVELIN™ also reduces false positive test results, helping to avoid unnecessary treatment of patients.3
References
1 J Endocr Soc. 2022 Jul 1; 6(7): bvac077. Andrew R Hoffman, Tracy Mathison, Deno Andrews, Kristine Murray, Nicky Kelepouris, and Maria Fleseriu - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165431/ -last accessed 1.3.2023
2 Yuen KCJ, Biller BMK, Radovick S, et al -. Endocr Pract. 2019;25(11):1191-1232. https://pubmed.ncbi.nlm.nih.gov/31760824/ - last accessed 1.3.2023
3 Garcia JM et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab, 2018, 103(8): 3083-3093 - https://pubmed.ncbi.nlm.nih.gov/29860473/ - last accessed 1.3.2023
4 https://www.ema.europa.eu/en/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf – last accessed 1.3.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA Recognized as a Global Top Employer for Third Consecutive Year15.1.2026 09:00:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announces it has been certified as a Global Top Employer for 2026 by the Top Employers Institute. Recognized for the third year in a row, this prestigious honor places NTT DATA among a select group of just 17 organizations worldwide honored for consistently delivering a high-performing people strategy across its global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115418660/en/ NTT DATA recognized as a Global Top Employer In addition to its global recognition, NTT DATA has also earned four Top Employer 2026 regional seals and 37 country and region seals across North America, Latin America, Asia Pacific, Europe and Africa. The Global Certification is the highest level of recognition offered by the Top Employers Institute and underscores NTT DATA’s ability to align its leadership, leverage data-driven insights and apply validated b
SAP and Syngenta Announce Partnership to Scale AI-Assisted Agriculture15.1.2026 09:00:00 CET | Press release
SAP SE (NYSE: SAP) and Syngenta, a global leader in agricultural innovation, today announced a multi-year strategic technology partnership to accelerate AI-assisted innovation across Syngenta’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115682130/en/ Jeff Rowe - CEO of Syngenta Group (left) and Christian Klein - CEO of SAP (right) The partnership will embed artificial intelligence at the core of Syngenta’s enterprise, modernizing operations and enabling accelerated innovation through advanced data analytics across the business — from manufacturing and supply chain to grower-facing products and services. Agriculture continues to navigate challenges driven by climate variability, supply chain complexity, and global uncertainty. By deploying AI-assisted tools enterprise-wide, this partnership positions Syngenta to meet the challenge of feeding a projected 10 billion people by 2050, while unlocking fast
Advanced Sterilization Products (ASP) Announces CE Mark for ULTRA GI™ Cycle for Duodenoscopes in Partnership with FUJIFILM Healthcare Europe15.1.2026 09:00:00 CET | Press release
New cycle for the STERRAD™ 100NX Sterilizer introduces a validated sterilization method for complex endoscopes, promoting patient safety through innovation. ASP International GmbH (“ASP”), a division of Fortive (NYSE: FTV), in collaboration with FUJIFILM Healthcare Europe GmbH, proudly announces that the ULTRA GI™ Cycle has received CE mark approval. The ULTRA GI™ Cycle is the latest innovation for the STERRAD™ 100NX Sterilizer with ALLClear™ Technology. The ULTRA GI™ Cycle’s receipt of the CE mark represents a pivotal advancement in elevating patient safety across healthcare facilities and addressing the complex challenges associated with traditional reprocessing methods. “This is a meaningful step forward in our mission to make duodenoscope reprocessing safer across Europe,” said Chad Rohrer, President, ASP. “By bringing hydrogen peroxide gas plasma sterilization into routine practice, we’re giving clinicians greater confidence to focus on what matters most – their patients.” ASP’s i
AWS Launches AWS European Sovereign Cloud and Announces Expansion Across Europe15.1.2026 08:00:00 CET | Press release
AWS announces the general availability of the AWS European Sovereign Cloud and plans to expand across Europe with new AWS Local Zones in Belgium, the Netherlands, and PortugalAmazon plans to invest more than €7.8 billion in the AWS European Sovereign Cloud in Germany and support an average of 2,800 full-time equivalent jobs annually Today, Amazon Web Services (AWS) announced the general availability of the AWS European Sovereign Cloud, a new, independent cloud for Europe entirely located within the EU, and physically and logically separate from other AWS Regions. The AWS European Sovereign Cloud’s unique approach provides the only fully featured, independently operated sovereign cloud backed by strong technical controls, sovereign assurances, and legal protections designed to meet the needs of European governments and enterprises for sensitive data. AWS also announced plans to extend the AWS European Sovereign Cloud footprint from Germany across the EU to support stringent isolation, i
Cargill Advances Maritime Decarbonisation with Delivery of First Green Methanol Dual-Fuel Vessel15.1.2026 08:00:00 CET | Press release
Brave Pioneer is the first in a new fleet of chartered vessels designed to scale Cargill’s investment to low-carbon innovation across dry-bulk shipping Cargill today announced the maiden voyage of Brave Pioneer, the first of five green methanol dual-fuel dry bulk vessels chartered by the company. The deployment of the Brave Pioneer marks another important milestone in Cargill’s broader decarbonization efforts – one focused on innovation, testing and learning as the company works with customers and partners to refine future-ready solutions for Cargill and the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114083757/en/ Built by Tsuneishi Shipbuilding Co., Ltd. and owned by Mitsui & Co. Ltd., Brave Pioneer is equipped to operate on both conventional marine fuels and green methanol, a lower-carbon alternative. Built by Tsuneishi Shipbuilding Co., Ltd. and owned by Mitsui & Co. Ltd., Brave Pioneer is equipped to ope
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom